Get started
UNITEDHEALTH GROUP INC CEDEAR EA 33 REP 1 COM(USD)UNITEDHEALTH GROUP INC CEDEAR EA 33 REP 1 COM(USD)UNITEDHEALTH GROUP INC CEDEAR EA 33 REP 1 COM(USD)

UNITEDHEALTH GROUP INC CEDEAR EA 33 REP 1 COM(USD)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

UNHD trade ideas

$UNH buy the fear or sell into narrative?- NYSE:UNH has gotten into trouble with bad headlines after bad headlines. - Recent DOJ probe led to 12% shaving in the stock price. - Could it be a buying opportunity or just a falling knife? - Are you afraid that NYSE:UNH could become NYSE:HUM 2.0? Let's talk about fundamentals! Year | 2024 | 2025 | 2026 | 2027 | 2028 GAAP EPS | 15.76. | 28.22 | 32.11 | 36.80 | 41.11 EPS growth% | -33.47% | 79.08% | 13.77% | 14.61% | 11.71% It appears that 2024/ Early 2025 was the year when EPS growth bottomed and would go from negative to positive back again. EPS growth is healthy double digit in mid teens. A fair forward p/e multiple for mid teen EPS growth should at least be 15 ( conservatively ) Year | 2024 | 2025 | 2026 | 2027 | 2028 Fair Stock Price (w/ forward p/e = 15 ) | $236 | $423 | $481 | $552 | $616 However, NYSE:UNH is a blue chip company and has a moat. Therefore, Investors will be willing to pay forward p/e of 20 once negative news subside. Year | 2024 | 2025 | 2026 | 2027 | 2028 Fair Stock Price (w/ forward p/e = 20 ) | $315 | $564 | $642 | $736 | $822.2 Final Take: I'm a buyer of NYSE:UNH < 450 will add more if it dips below 400 for the long term. Good quality companies don't usually buyers to get their skin into the game. Therefore, it's better to buy the fear than selling into narrative.
NYSE:UNHLong
by bigbull037
1
The Ugly Truth of Technical Analysis...Even though this may be an extremely unpopular opinion on this topic, realizing this simple truth may be what makes or breaks a profitable trader. The truth is this... Drawing lines on a chart does not predict any price movement, and there are more factors in play than simply price action It doesn't matter what the gurus on the internet say about some "secret strategy" or a "secret indicator", anyone with common sense should automatically ignore content like that. Firms like NYSE:JPM , NYSE:GS , NYSE:MS , etc. , spend billions upon billions of dollars just to figure out how to trade the market with efficiency, but some random 19 year old on the internet figured out how to beat these mega-firms with a free indicator. Yeah right. However, I'm not saying that technical analysis doesn't work or that it shouldn't be used; I'm simply saying to reconsider your strategy and use common sense before donating your money to Wall Street banks. Below is an example of technical analysis working perfectly on NYSE:UNH for the 1D timeframe looking back into April of last year. This would have been a textbook channel breakout trade, in which the trader takes a short when the bottom trendline is broken (or the candle closes below the trendline). It would have resulted in a maximum of 17% gain on naked short shares if the bottom penny is the exit price (which is virtually impossible). So there you have it... technical analysis works perfectly and I have proven myself wrong.... right? No. . Now let me show you what really happened. Here is the same exact chart, but this time with a piece of key information shown. As it turns out, there was nothing technical in play at all in this price action, but rather a "fundamental" or a "tangible" aspect was the price driver. An example like this should also show you that not providing sufficient information and taking charts out of context can be done by literally anyone. If you think you can predict the future with some geometric shapes, bars, and non financial, fundamental, or tangible analysis, better than the top Wall Street firms, I say good luck to you. WITH THAT BEING SAID, this does not mean that trendlines, price areas, value gaps, and other technical indicators are completely invalid, but it does mean that there is more to the story than what is on the chart. Always review news, sentiment, financials, analyst ratings, and other key oscillators to gauge every trade. Disclaimer: The indicators used on the chart are only for illustrative purposes of a cluttered chart. I am neither saying that they are accurate nor inaccurate.
NYSE:UNH
by addatheriver0808
UNH Stock Analysis: Potential Reversal Zone in a Downward ImpulsNYSE:UNH (UnitedHealth Group) appears to be in a downward impulsive wave, currently within the fifth wave. I anticipate a potential bounce near the blue horizontal line, which could act as a key support level. This analysis highlights a possible reversal zone, but keep in mind that this is not financial advice or a recommendation to buy or sell. Always monitor price action and volume closely to confirm any movement. #UNH #StockAnalysis #TechnicalAnalysis #TradingView #StockMarket #ElliottWave #SwingTrading
NYSE:UNHShort
by omossa
UNITEDHEALTH GROUP | THE BEAR'S CLAIM: $UNH PAYS THE PRICE Dec17UNITEDHEALTH GROUP | THE BEAR'S CLAIM: NYSE:UNH PAYS THE PRICE Dec17 UnitedHealth Group, NYSE:UNH , UNH NYSE:UNH Trends: NYSE:UNH Weekly Trend: Bearish NYSE:UNH Daily Trend: Bearish NYSE:UNH 4H Trend: Bearish NYSE:UNH 1H Trend: Bearish NYSE:UNH Price Target Areas: NYSE:UNH BUY/LONG ZONE (GREEN): $488.75 - $514.75 NYSE:UNH DO NOT TRADE/DNT ZONE (WHITE): $480.00 - $488.75 NYSE:UNH SELL/SHORT ZONE (RED): $455.00 - $480.00 All indicators are pointing to bearish for $UNH. Looking at the monthly timeframe we can see there is a range that was respected between the levels of 480 up to 555. After price finally broke the level of 555 a new range began. 560 up to 615/620 area. Given the recent news and events; the stock has since seen a deep bearish trend. Momentum has taken price all the way back down to the previous range low of 480. Price currently rests on 480. Bears should seek continuation and target levels of 455/460, or even down to 415. Bulls should look for a reversal marked by breaks over 488.75 on the lower timeframes, or the 549 area for a higher frame reversal. This is what I would personally look at before entering trades, everything is subject to change on a daily basis and as I analyze different timeframes and ideas. ENTERTAINMENT PURPOSES ONLY, NOT FINANCIAL ADVICE! trendanalysis, trendtrading, priceaction, priceactiontrading, technicalindicators, supportandresistance, rangebreakout, rangebreakdown, rangetrading, chartpatterntrading, chartpatterns, unh, unitedhealth, unitedhealthgroup, NYSE:UNH , insurance, insuranceclaims, unhinsurance, unhclaims, unhdeductible, unhstock, unhprice, unhtarget, unhsetup, unhtrade, unhzone, medicare, unhanalysis, unitedhealthanalysis, unhtradeidea, unhidea, unhrecentevents,
NYSE:UNHShort
by TonyAiello
Bullish on UnitedHealth Group. UNHMajor confluence of factors here to suggest a bullish bias. MIDAS curve cross shortly after Ehrler's Smoother cross. Suspect B Wave start in a flat zigzag. Ehrler's stochastic and VZO remain bullish, yet less convincingly. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green or purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Professionally, we are big fans of any indicators from Jurik, De Mark and Ehlers, which we use in addendum in analysis prior to putting down positions. We prefer a combination of at least four technical factors to favor a particular stance. A stance is never decided by this constellation, rather the constellation merely confirms the stance. Trading is a true one man sport. No single confluence of indicators is truly good enough, and a professional trader's sense must be developed through a lot of hard work and over a significant period of time. Good luck out there and stay safe.
NYSE:UNHLong
by Rykin_Capital
United Health Group - Innovation in the Medical BusinessHi guys, off to our next analisys we would be taking a look into UNH. UnitedHealth Group continues to shine as a leader in the healthcare industry, showcasing exceptional financial health and a promising future. The company's strong financial performance, driven by innovative solutions and a focus on operational excellence, reflects its ability to adapt and thrive in a complex and ever-changing market. UnitedHealth Group's dedication to improving healthcare outcomes through technology and data-driven approaches sets it apart. Their forward-looking investments in cutting-edge medical advancements and digital health tools demonstrate a commitment to delivering accessible, high-quality care for individuals and communities. The company’s diversified business model, spanning insurance services and healthcare delivery, provides a solid foundation for sustained growth. Their strategic initiatives, including expanding partnerships and entering new markets, further position them as a trailblazer in the healthcare sector. UnitedHealth Group's unwavering focus on customer-centric solutions, combined with its financial strength and visionary leadership, ensures a future of continued success. For stakeholders and investors, UnitedHealth Group is not only a secure choice but also an inspiring partner in shaping the future of healthcare. My entry would be: 500 I would enter with 300 shares Target 1: 553 Target 2: 625 As always my friends happy trading! P.S. If you have questions or inquiries about one of my existing set-ups or personal questions / 1 on 1 sessions consider joining my community so you can follow up with me in private!
NYSE:UNHLong
by DG55Capital
UNH | UnitedHealth Group (UNH) | BearishNYSE:UNH Technical Analysis of UnitedHealth Group (UNH) Key Observations: Current Price Action: Price: $498.50 Recent Drop: -21.98 (-4.22%) Support and Resistance Levels: Immediate Support: $475.87 (Target Price 1) Further Supports: $436.72 (Target Price 2) Resistance: The price recently broke below previous support around $525-$530, confirming bearish momentum. Trendlines: The price has clearly broken below a key upward trendline. The breakdown signals a shift from a bullish to a bearish trend, with lower highs (LH) and lower lows (LL) forming. Relative Strength Index (RSI): Current RSI: Below 30 (Oversold Zone). The RSI indicates heavy selling pressure, suggesting the stock may be oversold, but bearish momentum remains intact. Target Prices: Target Price 1: $475.87 This level acts as immediate support where price could pause or consolidate. Target Price 2: $436.72 If the price breaches the $475.87 level, the next key support lies at $436.72. Summary: UnitedHealth Group (UNH) is showing clear bearish signs, having broken below critical support and its upward trendline. The RSI indicates an oversold condition, but momentum remains downward. Key levels to monitor are $475.87 (Target 1) and $436.72 (Target 2). Any recovery will need to overcome resistance at $525-$530 for a trend reversal.
NYSE:UNHShort
by shkspr
UNH Selloff Unreasonable - Still 15% ROI Short-TermSince my first NYSE:UNH idea a couple of days ago the price of this stock dropped significantly. If you've been part of the first idea you should've been able to lock in around 1.x% of return when using a tight stop-loss. Otherwise you've been stopped out with break-even. Nevertheless, the sell-off was not helpful and is completely exaggerating the situation at UNH since the company is not really effected by the current PBM debate. "Deutsche Bank sees a potential divestiture as not having a significant impact on earnings, estimating the risk at likely less than $200M of the company’s roughly $30B+ operating earnings. Deutsche Bank noted, however, that CVS (CVS), Cigna (CI) and UnitedHealth (NYSE:UNH) 'could face additional risk from losing the ability to vertically integrate the PBM, fulfillment and manufacturing functions of biosimilars through organizations like Cordavis and Quallent.' Despite concerns about the potential breakup of their pharmacy businesses, Deutsche Bank maintained it's buy rating on UnitedHealth (UNH)." From a technical standpoint we can see a confluence of support: Weekly SMA200 Strong Trendline from March 2020 Horizontal Support at $480 UNH managed to bounce from the trendline intraday today. This could mean we're going to see a turnaround from here. If we break below the trendline on the daily chart this trade will be invalidated. Otherwise our target sits at $550.
NYSE:UNHLong
by LGNDRY-Capital
1
Buy Recommendation Note for UnitedHealth Group (UNH)Recommendation: Buy Buy Zone: $551.50 - $557.00 Target: $600.00 (Short-Term), $650.00 (Medium-Term) Rationale Strong Fundamentals: UnitedHealth Group has consistently delivered robust revenue growth driven by its diversified healthcare services and insurance offerings. Industry Leadership: As a leader in the healthcare sector, UNH benefits from its scale, market share, and innovative healthcare solutions, ensuring long-term stability. Positive Outlook: Recent developments and earnings reports indicate strong growth potential, supported by increasing demand for managed healthcare services. Valuation: Current levels provide a favorable risk-to-reward ratio for entry, with the stock trading near a key support zone. Technical Analysis The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones. Technical Analysis The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones. Disclaimer: This note is for study and informational purposes only. The recommendations and price levels mentioned are based on market observations and are not a guarantee of performance. Please consult with a licensed financial advisor and carefully consider your risk tolerance before making any investment decisions. Past performance is not indicative of future results. Investing in stocks carries inherent risks, including the potential loss of capital.
NYSE:UNHLong
by KSLBroking
4
Unitedhealth Stock Qoute | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Unitedhealth Stock Qoute - Double Formation * 550.00 USD | Trend LIne Survey | Subdivision 1 * Retracement | Uptrend Bias | Main Entry At 485.00 USD - Triple Formation * Pattern Confirmation & Neckline Conditions Valid * 495.00 USD Trend Line Survey | Subdivision 2 * Flag Pattern & Top / Bottom Structure | 50% Retracement | Subdivision 3 Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell
CAPITALCOM:UNHShort
by TradePolitics
UHC is TOASTLooks like UHC might gap lower tomorrow morning; in addition to a rather robust sell-off today, hourly net volume was negative for every hour today. And of course...they've been exposed as a company likely to break insurance contracts 32% of the time. Their current CEO insinuated that his workers were in the "healthcare industry" because they "care". Insurance companies are not in the healthcare industry...they're in the insurance/finance industry...the more "retained premiums" the more they have to "invest" in the stock market, fx, metals, commodities...they're literally in every market like giant hedge funds. Luckily, this horrid event happened before seniors made their annual choice for Medicare Advantage plans and the news UHC denied 32% of claims likely turned off any Medicare users. Feel pretty sure private companies are going to eliminate UHC as a choice in their insurance offerings, same for governments. Feel like this company is toast and it's only the beginning.
NYSE:UNHShort
by mbslack1
2
A "Resistance Becomes Support" Example with UNH?Looking at the weekly chart of UnitedHealth Group (UNH), here’s the resistance area I’ve marked in red: 1.April 11, 2022: $555 area rejected, and the stock sells off to $448. 2.August 15, 2022: $555 area rejected, and the stock sells off to $490. 3.October 31, 2022: Briefly touches $558, then sells off to $448. 4.November 27, 2023: $555 area rejected, and the stock sells off to $437. In the week of July 15, 2024, the stock finally broke above this resistance level that had persisted for nearly three years. There are strong fundamentals behind this move. I’ve marked two instances where the stock has since come back down to this level (green 1&2), and am watching closely to see if it will continue to hold as support. If it does, my first target is the $610 area.
NYSE:UNHLong
by onlytrade2win
1
UNH Bounce - Don't Miss Out On This 15% OpportunityNYSE:UNH dropped after the tragic death of UnitedHealthcare CEO (not UNH Group CEO) as well as public backlash. Nevertheless, as always in such situation, this has nothing to do with the stock itself. As price action traders we do not trade political or news events since those drops have an unimportant impact mid- to long-term. UNH now sits on the support zone at around $550 which was previous resistance. We also filled the daily gap at around $568 completely. We touched the 0.236 Fib from the $273 bottom (from 2020) and the RSI is nearly oversold on the daily. This gives us a got chance for a bounce from this zone up to $600 - $620. Support Levels: $550 $528 Target/Resistance Levels: $600 $622-628
NYSE:UNHLong
by LGNDRY-Capital
1
$UNH Bad News Longs.NYSE:UNH Recent news should (I believe will) put an end to the madness imaginary run from the corrupt world of health insurance. News circulating NYSE:UNH was a top denier of benefits and claims, only will get worse. A CEO involved in a hit sh**ting? They won't find the "guy" and I assume they will make an arrest but not the actual one who did it. Mmn, conspiracy, yes. But, similar pattern evolving on the chart as well, almost like it all makes sense. Might be a good time to short the health/insurance sector.. maybe.. BlueCross BlueShield just cut back on paying for patients anesthesia in NY, CT, and MO. They are against the people.. biggest ponzi-scheme ever. $555 target, break $500 I see $530. A lot of bearish flow poured in today as well. Months out puts. Not financial advice. wall street .. loser
NYSE:UNHShort
by wallstreetloser001
Ride the green wave to $800 $UNH Elliott Wave Analysis of UNH on Monthly Chart Elliott Wave Theory posits that stock price movements follow a predictable wave structure, typically broken down into five impulsive waves (1, 2, 3, 4, and 5) in the direction of the primary trend, followed by a corrective wave pattern (A, B, C) that moves against the trend. Identifying the current wave for UNH on a monthly chart allows us to make projections for the next potential targets. Current Wave Structure Analysis Wave 1 (Start of the Bull Market): The initial wave (Wave 1) likely began during a period of recovery, typically marking the start of a longer-term uptrend for UNH. This initial move sets the foundation for the subsequent waves. Wave 2 (Corrective Phase): After Wave 1, a corrective move (Wave 2) generally retraces a significant portion of the initial rally, often around 50%–61.8% according to Fibonacci retracement levels, before finding support and resuming the primary uptrend. Wave 3 (Strongest Impulse Wave): Wave 3 tends to be the longest and most powerful wave in the Elliott cycle, often experiencing a price increase of 161.8% or more relative to Wave 1. UNH experienced significant growth in this phase, with accelerated price movement, driven by robust fundamentals and growth in both the UnitedHealthcare and Optum segments. Wave 4 (Consolidation): The stock may currently be consolidating in Wave 4, which is typically a corrective or sideways movement, allowing the stock to "catch its breath" before a potential final rally in Wave 5. Wave 4 corrections are often shallow, retracing 38.2% or less of Wave 3’s movement and providing a setup for the final impulse. Wave 5 (Potential Target Zone: $800+ Level): If UNH is indeed in the latter part of Wave 4, the upcoming Wave 5 could be the final leg in this uptrend. Wave 5 generally aims to surpass the high of Wave 3, often aligning with Fibonacci extension levels, such as 100% or 161.8% of the length of Wave 1. Targeting $800 with Fibonacci Extensions Using Fibonacci extension levels can give us specific price targets within Wave 5: Primary Target Zone: 100% Extension of Wave 1: This level often serves as the initial target for Wave 5, potentially placing UNH within reach of the $750–$775 range. Secondary Target Zone: 161.8% Extension of Wave 1: If Wave 5 proves to be a stronger rally, it could extend further, targeting the $800+ range, potentially even higher, depending on market momentum. Alternate Scenario - Extended Fifth Wave: In some cases, a fifth wave can extend more significantly if momentum builds in the final stages. In this scenario, UNH could surpass $800, although such extensions are less common and would depend heavily on continued fundamental support. Supporting Momentum Indicators RSI and MACD Divergence: Momentum indicators such as the RSI and MACD can signal wave exhaustion. If these indicators diverge (showing lower highs while price hits higher highs), it could signal the end of Wave 5. Volume Analysis: Volume spikes often accompany the end of impulsive waves, so increased trading volume around the $800 level may indicate that the wave is approaching completion. Summary Current Position: Likely in Wave 4 consolidation or early stages of Wave 5. Primary Target: $750–$775 (100% extension of Wave 1). Secondary Target: $800+ (161.8% extension, depending on momentum). Risk Factors: Watch for momentum divergence and volume spikes, which could signal a peak in Wave 5. This analysis aligns with the potential for UNH to reach $800 in the coming months, assuming the Elliott Wave structure remains intact. Strong Financial Performance and Earnings Growth UNH has consistently posted strong financial results, outpacing many peers in the healthcare sector. Its latest earnings reports have shown impressive revenue and profit growth, attributed to both organic expansion and strategic acquisitions. Key performance metrics to support an $800 price level include: Revenue Growth: UNH’s revenue is projected to grow at a stable rate due to increased healthcare spending, particularly in Medicare and Medicaid, as well as continuous innovations in service delivery. Earnings Per Share (EPS) Growth: EPS has seen a consistent increase over the past years, supported by margin expansions in the UnitedHealthcare and Optum segments. Profit Margins and Cash Flow: With robust cash flow and prudent cost management, UNH has been able to invest in technology, expand healthcare services, and maintain shareholder value through dividends and share buybacks, all factors supporting stock price appreciation. UnitedHealth Group’s Upcoming Investor Conference UnitedHealth Group (UNH), a global leader in healthcare services, is expected to host its annual Investor Conference in late November 2024. This highly anticipated event will bring together investors, analysts, and industry experts to discuss UnitedHealth Group’s strategic growth priorities, recent performance, and outlook for 2025.
NYSE:UNHLong
by PublicizePays